BTIG Research Forecasts Strong Price Appreciation for SOPHiA GENETICS (NASDAQ:SOPH) Stock

SOPHiA GENETICS (NASDAQ:SOPH) had its price objective increased by equities research analysts at BTIG Research from $6.00 to $7.00 in a research note issued on Monday,Benzinga reports. The firm currently has a “buy” rating on the stock. BTIG Research’s price target indicates a potential upside of 60.18% from the company’s current price.

SOPH has been the subject of several other research reports. Wall Street Zen upgraded SOPHiA GENETICS to a “hold” rating in a report on Saturday, November 1st. Weiss Ratings restated a “sell (d-)” rating on shares of SOPHiA GENETICS in a research note on Wednesday, October 8th. Two analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $9.00.

SOPHiA GENETICS Price Performance

SOPH stock opened at $4.37 on Monday. The company has a debt-to-equity ratio of 0.78, a current ratio of 2.80 and a quick ratio of 2.62. The company’s 50-day moving average is $4.02 and its 200-day moving average is $3.48. The stock has a market capitalization of $295.32 million, a PE ratio of -9.50 and a beta of 1.10. SOPHiA GENETICS has a 1 year low of $2.58 and a 1 year high of $5.30.

SOPHiA GENETICS (NASDAQ:SOPH) last issued its earnings results on Tuesday, November 4th. The company reported ($0.30) EPS for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.10). SOPHiA GENETICS had a negative net margin of 41.13% and a negative return on equity of 37.75%. The firm had revenue of $19.46 million during the quarter, compared to the consensus estimate of $18.13 million. SOPHiA GENETICS has set its FY 2025 guidance at EPS. Equities research analysts expect that SOPHiA GENETICS will post -0.96 EPS for the current fiscal year.

Institutional Trading of SOPHiA GENETICS

Several institutional investors have recently made changes to their positions in SOPH. GSA Capital Partners LLP purchased a new stake in shares of SOPHiA GENETICS in the third quarter valued at about $59,000. Savvy Advisors Inc. bought a new stake in SOPHiA GENETICS in the 3rd quarter worth about $48,000. Alta Wealth Advisors LLC purchased a new stake in SOPHiA GENETICS in the 3rd quarter valued at about $6,708,000. Akre Capital Management LLC lifted its position in shares of SOPHiA GENETICS by 66.2% during the 2nd quarter. Akre Capital Management LLC now owns 3,719,140 shares of the company’s stock worth $11,529,000 after buying an additional 1,481,636 shares in the last quarter. Finally, Federated Hermes Inc. boosted its stake in shares of SOPHiA GENETICS by 16.4% in the 2nd quarter. Federated Hermes Inc. now owns 220,000 shares of the company’s stock worth $682,000 after buying an additional 31,000 shares during the last quarter. Institutional investors own 31.59% of the company’s stock.

About SOPHiA GENETICS

SOPHiA GENETICS SA operates as a cloud-native software technology company in the healthcare space. The company offers SOPHiA DDM platform, a cloud-native software platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, applications, products, and services are used by hospitals, laboratories, and biopharmaceutical companies through its own sales force as well as distributors and industry collaborators in Switzerland, France, Italy, rest of Europe, North America, the United States, Latin America, and the Asia-pacific.